The effect ot tetrahydro-9-ammoacndme (THA) and related compounds on hgand binding to the &sso-clatwe anesthetic (phencychdme, PCP) receptor site was assessed using a rat brain homogenate assa'y THA displaced the &ssoclatwe anesthetic hgand THA has a complicated pharmacology It has been found to reverse morphine arid magnesium chloride induced coma [13] and to attenuate the intensity of narcotic withdrawal symptoms [3, 15] It is a potassium and sodium channel blocker [12, 14] It has also been found to decrease the duration of anesthesia induced by the dissociative anesthetics, phencychdlne (PCP) and ketamme [1, 2, 4], as well as to reduce the emergence symptoms associated with ketamine anesthesia in both man and animals
The effect ot tetrahydro-9-ammoacndme (THA) and related compounds on hgand binding to the &sso-clatwe anesthetic (phencychdme, PCP) receptor site was assessed using a rat brain homogenate assa'y THA displaced the &ssoclatwe anesthetic hgand
binding with an ICs0 of 26 uM Other acridine derlvatzves &splayed similar potency as &splacers ol [~H]TCP Chohnesterase mhlbltors and ammopyrtdmes had ICs0s equal to or greater than 100/tM Saturation studies of [~HITCP m the presence and absence of 30 pM THA revealed competitive mhlbltlon with a K~ ot 15/tM The chmcal pharmacology of THA suggests that it antagomzes the effects o! dJssoclatl~e anesthet~t~s whereas m vitro, it behaves as a weak PCP agomst THA may exert some of Its chmcal effects through interaction with the PCP receptor and may have mixed agomst antagomst properties Tetrahydro-9-aminoacridine (THA) is an orally administered, centrally active chohnesterase inhibitor recently reported to ameliorate significantly the cognitive deficits of dementia of the Alzhelmer's type (DAT) [16] While the effects of THA have been attributed to ~ts action as a chohnesterase mhlbltor, clinical trials of other chohnesterase lnhlbitors have yielded unimpressive results [6] This discrepancy suggests that THA may have additional modes of action THA has a complicated pharmacology It has been found to reverse morphine arid magnesium chloride induced coma [13] and to attenuate the intensity of narcotic withdrawal symptoms [3, 15] It is a potassium and sodium channel blocker [12, 14] It has also been found to decrease the duration of anesthesia induced by the dissociative anesthetics, phencychdlne (PCP) and ketamme [1, 2, 4], as well as to reduce the emergence symptoms associated with ketamine anesthesia in both man and animals
[1.4]
PCP receptor density decreases have been documented in DAT [10, 11] The PCP receptor is functionally associated with the N-methyl-D-aspartate (NMDA) subtype of excitatory ammo aod receptors and NMDA receptor density also dechnes m DAq [8] NMDA receptors are particularly promment m the hlppocampus where the brunt of DAT pathology falls Because THA apparently antagomzes some of the effects of PCP-hke drugs, we stu&ed the possible interaction of THA and structurally related compounds with the PCP receptor site We also studied the effects of other chohnesterase mhlbltors and structurally related potassmm channel blockers Rat forebram membranes were homogemzed m 50 mM Tns-acetate buffer (pH 7 0 at 4°C) with a Polytron at a setting of 7 Membranes were then centrifuged for 20 mm at 20,000 g The pellet was resuspended m 50 mM Trls-acetate buffer, (pH 7 0 at room temperature) Varying concentrations of THA and related compounds were incubated with prepared membranes and the specific PCP hgand [3H]N-(1-[2-thlenyl]-cyclohexyl)-3,4-plperldme (TCP) at a concentration of 10 nM Trlphcate samples were incubated for 30 mm at room temperature, then filtered over GF/B glass filters Fdters were washed twice wRh 4 ml 50 mM Tns-acetate buffer (pH 7 0 at 4°C) All filters were pre-soaked in 0 5% polyethylenelmme to ehmlnate binding of [3H]TCP to the filters Filters were immersed m 5 ml aqueous counting solution (Amersham) and ra&oactwlty determined m a Beckman LS 8100 sclntdlatlon counter Non-specific binding was assessed with the addmon of 10/tM TCP THA displaced [3H]TCP with an IC50 of 26/tM (Table I) The acridine denvatwes 9-ammoacndlne and proflawn were of comparable potency (Table I) The chohnesterase inhibitor neostlgmme had an IC50 greater than 100/IM Two other chohnesterase mhlbltors, physostlgmme and edrophomum, had ICs0s of 100/tM Three amino (Fig I) In the presence of 30 ILM THA the mean Ka was 117 nM (S D ---57 13, n = 3) and mean Bma x was 748 fmol/mg protein (S D = 195, n = 3) (Fig 1) , indicative of competitive inhibition Double-reciprocal plots confirmed competitive inhibition with a mean K, of 15/IM (S D = 6 62, n = 3) At a concentration of 300/tM, THA had no effect on NMDA receptor binding in a sensitive autoradlographic assay (data not shown) Preliminary experiments in&-cate that THA also displaces the PCP hgand MK-801
Davenport et al have examined the effects of THA and related compounds on NMDA mediated neurotoxlclty and neuroexcltatlon [7] They found that THA was a moderately effective antagonist of NMDA, that chohnesterase lnhlbltors were weak antagonists, and that the potassmm channel blocker 4-amlnopyrldlne had no NMDA antagonist properties This rank order of potency accords well with our binding data Drugs active at the PCP receptor are thought to block NMDA responses noncompetltlvely through actions at the cation channel associated with the NMDA receptor [5] THA is a known potassium and sodium channel blocker and the closely related compound 9-ammoacndlne is a sodium channel blocker [17] duration of anesthesm and emergence symptoms assocmted w~th d~ssocmtlve anestheslcs Thts suggests that THA antagontzes the effects of dlssoclattve anesthettcs These data, together wtth those of Davenport et al, suggest that THA may have mixed agomst-antagomst properties at the PCP receptor No PCP antagomst has yet been found and such an agent could be of great mterest The antagomsm of THA for NMDA could ltmlt the effectiveness of THA m DAT Decreases in PCP/NMDA receptors in DAT are particularly prominent tn the htppocampus In addmon to being a focus of pathology in DAT, it is known that the major afferent projection to the hlppocampus, the perforant pathway, is seriously affected m DAT [9] This pathway is felt to be glutamaterglc and deficiencies m glutamate neurotransmlsslon may contrtbute to the memory defiots of DAT Further decreases m NMDA medmted neurotransmlsslon m the hlppocampus could exacerbate the memory deficits of DAT On the other hand, should THA prove to have PCP antagonist properties tt could potenttate NMDA receptor neurotransmlsston Even a modest increase m the effioency of glutamatergtc neurotransmlsslon m the htppocampus could be of benefit m DAT Fmally, it should be pointed out that the/(I of THA for TCP bmdmg is considerably higher than the reported effecttve serum concentration of THA The effecttve bram concentratton is unknown and a proper assessment of the relevance of our findrags awaits determmatton of this value We thank Maunce S Albm for the donation of THA, Zane Holhngsworth for techntcal asststance, Jang-Ho Cha for figure preparation, and Suym Lmng for manuscrtpt preparatton Supported by NIH Grant 5-T32-NS07222-05, and USPHS Grant AG 06155
